Cytidine deaminase cDNA as a positive selectable marker for gene transfer, gene therapy and protein synthesis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 4, 2000
Grant Date -
N/A
app pub date -
Oct 27, 1997
filing date -
Jul 31, 1995
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention relates to a DNA sequence for the human cytidine deaminase that has been engineered into an eukaryotic expression vector, thereby permitting cytidine deaminase expression in mammalian cells. Cytidine deaminase expression confers resistance to cytosine nucleoside analogs, such as cytosine arabinoside, and can be used as a positive selectable marker. The expression of cytidine deaminase in cells protects them from the toxic effects of cytosine nucleoside analogs. Such a resistance provides applications for gene therapy of malignant, immune and viral diseases. A bacterial expression vector containing the gene can be used to produce cytidine deaminase in large quantities.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully